Immuneering is a new medicine developer that leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods.
Immuneering offers medical data evaluation, biological information, data management, and pharmaceutical development. Immuneering develops medicines for cancer, autoimmune, neurodegeneration, and other diseases.
Immuneering was founded in 2008 by Bob Carpenter and Ben Zeskind. The company is headquartered in Cambridge, Massachusetts, with offices in San Diego, California and New York, New York.
Immuneering's current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. Utilizing its proprietary Disease Cancelling Technology, the company engineers medicines that reverse a disease signal across many relevant genes.
Immuneering’s technologies have proven exceptionally rapid and capital efficient in creating its pipeline. Concurrent with its internal programs, the company provides unparalleled computational biology services to leading pharmaceutical and biotechnology companies.
Immuneering is backed by Boxcar PMJ LLC. The company has closed its oversubscribed Series A round at a total of $20M on Jan 22, 2020.